Previous Pause Next
Home >> News Center >>
Enterprise & Industry
Roche Seeks "Targeted Acquisitions," Not Abbott Laboratories-Sized Deal PDF Print E-mail
Monday, 24 October 2011 01:01

Roche Holding AG will maintain a strategy of “targeted acquisitions” and isn’t seeking a mega- merger, Chief Executive Officer Severin Schwan said in comments that may rule out a bid for Abbott Laboratories’ prescription- drug spinoff.

Read more...
 
Dynavax Technologies Corporation and GlaxoSmithKline Expand Their Worldwide Strategic Alliance to Up to $203 Million PDF Print E-mail
Sunday, 23 October 2011 00:55
RKELEY, CA, Oct 21, 2011 (MARKETWIRE via COMTEX) -- Dynavax Technologies Corporation announced today the expansion of its worldwide strategic alliance with GlaxoSmithKline (GSK) focused on toll-like receptor (TLR) inhibitors. The addition of a new target, TLR8, entitles Dynavax to receive a $3 million milestone payment from GSK. Subject to reaching sales and development milestones, Dynavax has the potential to receive approximately $200 million in milestone payments over the term of the alliance. Based on preclinical data, Dynavax and GSK will work to develop a TLR8 inhibitor for the treatment of multiple autoimmune and inflammatory diseases.
Read more...
 
Auris Medical AG Reporting Positive Results from Phase 2b Trial With AM-101 for the Treatment of Acute Inner Ear Tinnitus PDF Print E-mail
Thursday, 20 October 2011 00:42
Auris Medical announced today positive results from a phase IIb clinical trial with AM-101, its investigational drug for the intratympanic treatment of acute inner ear tinnitus. The study demonstrated that the treatment was very well tolerated and showed a statistically significant treatment effect. 
Read more...
 
KV Pharmaceutical Sues Former CEO $37 Million in Benefits PDF Print E-mail
Thursday, 20 October 2011 00:37

KV Pharmaceutical Co. has filed a lawsuit against its former board chairman and chief executive, Marc Hermelin, hoping to avoid paying him about $36.9 million in retirement benefits, plus legal expenses.

Read more...
 
FDA Approves ApoPharma's Deferiprone for Iron Overload PDF Print E-mail
Wednesday, 19 October 2011 00:22
The U.S. Food and Drug Administration today approved Ferriprox (deferiprone) to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy.
Read more...
 
Humana, Inc. and Pfizer Inc. Form Research Partnership to Improve Health Care Delivery for Seniors PDF Print E-mail
Tuesday, 18 October 2011 00:19
Humana Inc. (NYSE:HUM - News) and Pfizer Inc. (NYSE:PFE - News) today announced a five-year research partnership to explore new ideas and ways to improve the quality, outcomes and costs of the health care delivery system for senior citizens and other populations.
Read more...
 
K-V Pharmaceutical Company (KV-A) Shares Surged as Medical Groups Clarify Stance On Makena PDF Print E-mail
Tuesday, 18 October 2011 00:13

K-V Pharmaceutical Company (the "Company") appreciates the decision of the American College of Obstetricians and Gynecologists (ACOG) and Society for Maternal-Fetal Medicine (SMFM) to issue an information update and ensure that healthcare providers, patients, and the payer community have the facts regarding FDA-approved Makena(TM).

Read more...
 
Ranbaxy recalls three drugs from UK market PDF Print E-mail
Monday, 17 October 2011 00:50

The British arm of Ranbaxy Labs is in the process of recalling three drugs from the UK market. The drug firm has been asked by the UK drug regulator — Medicines and Healthcare products Regulatory Agency — to withdraw one batch each of antiviral drug Aciclovir,

Read more...
 
Galapagos NV Announces Second Extension to Services Collaboration with Chiesi Farmaceutici SpA PDF Print E-mail
Saturday, 15 October 2011 00:52
Galapagos NV (Euronext: GLPG) announced today that its BioFocus service division has extended its collaboration with Chiesi Farmaceutici, a privately owned Italian pharmaceutical company, for a second time. This extension of the collaboration with Chiesi is valued at EUR2.8 million.
Read more...
 
Sequenom Inc. to Bring 242 Jobs in Research Triangle Park PDF Print E-mail
Saturday, 15 October 2011 00:32

Genetic research firm Sequenom Inc. has announced that it will construct an $18.7 million molecular diagnostics laboratory at the N.C. Biotechnology Center campus inside Research Triangle Park. The move is expected to create 242 new jobs in RTP by 2015.

Read more...
 
Merck KGaA to Return Safinamide Rights to Newron Pharmaceuticals, Citing "Limited Market Potential" PDF Print E-mail
Monday, 24 October 2011 00:46

Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announced today that Merck Serono, a division of Merck KGaA, Darmstadt Germany, is returning global rights to safinamide to Newron effective in 180 days. The decision by Merck Serono is due to strategic considerations and re-prioritization of its R&D pipeline, and is not based on any new efficacy or safety findings with safinamide.

Read more...
 
Allos Therapeutics, Inc., AMAG Pharmaceuticals, Inc. Merger Called Off PDF Print E-mail
Sunday, 23 October 2011 00:51
WESTMINSTER, Colo.--(BUSINESS WIRE)-- Allos Therapeutics, Inc. (Nasdaq:ALTH - News) announced today that the Agreement and Plan of Merger and Reorganization (“the Merger Agreement”) entered into by and among Allos, AMAG and Alamo Acquisition Sub, Inc. on July 19, 2011, as amended on August 8, 2011, has been terminated. The Merger Agreement was terminated following the October 21, 2011, special meeting of AMAG stockholders at which AMAG's stockholders voted against the issuance of shares of AMAG common stock to Allos’ stockholders in the proposed merger. Separately, a majority of Allos’ stockholders voted in favor of the adoption of the Merger Agreement at a special meeting of Allos stockholders also held on October 21, 2011.
Read more...
 
Lpath, Inc. Initiates Dosing of iSONEP in Second of Two Proof-of-Concept Trials PDF Print E-mail
Thursday, 20 October 2011 00:40
Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, has initiated dosing in its Nexus clinical trial, in which iSONEP™ is being investigated as a treatment for wet AMD (age-related macular degeneration).
Read more...
 
Takeda Pharmaceutical Co. Ltd. to Focus on Integration Versus Mergers for Near Future, Executive Says PDF Print E-mail
Wednesday, 19 October 2011 00:24

Takeda president Yasuchika Hasegawa said that following its acquisition of Nycomed, the drugmaker has no near-term plans for another large-scale merger and acquisition, The Wall Street Journal reported Friday. "We would like to focus on integration for the next year or two. We don't have the capacity for big acquisitions, but maybe small ones," he indicated.

Read more...
 
VIVUS, Inc. Resubmits FDA App for Obesity Drug Qnexa PDF Print E-mail
Wednesday, 19 October 2011 00:19
Vivus Inc said it resubmitted the approval application for its obesity pill Qnexa to U.S. health regulators.

The U.S. Food and Drug Administration had denied approval for Qnexa last October and asked for evidence that higher heart rate associated with the drug does not increase the risk of major heart problems.

Read more...
 
Cytomedix Announces Option Agreement With Global Pharmaceutical Company for Distribution of AutoLogel System in Chronic Wound Market PDF Print E-mail
Tuesday, 18 October 2011 00:18

Cytomedix, Inc. (OTCBB:CMXI) (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, announced today the execution of a letter agreement granting an undisclosed global pharmaceutical company an exclusivity period until December 31, 2011 to conduct further due diligence regarding the AutoloGel™ System. In exchange, Cytomedix will receive a $2 million non-refundable option fee within 15 days.

Read more...
 
Medivation says prostate cancer drug may have edge PDF Print E-mail
Monday, 17 October 2011 00:52

Medivation Inc (MDVN.O), which expects key data this year from a pivotal trial of its experimental prostate cancer drug, believes the medicine could have competitive advantages over current therapies.

Read more...
 
Bristol-Myers Skin-Cancer Drug Yervoy Rejected by U.K. Health Cost Agency PDF Print E-mail
Monday, 17 October 2011 00:47

Bristol-Myers Squibb Co. (BMY)’s Yervoy drug was rejected by the U.K.’s health-cost agency, which suggested the company consider lowering the price of the skin- cancer treatment.

Read more...
 
Intellikine Initiates Phase I Study of Targeted Cancer Therapeutic INK1117 PDF Print E-mail
Saturday, 15 October 2011 00:49
Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that the first patient has been treated in a Phase I dose escalation study of INK1117 in patients with advanced solid malignancies.
Read more...
 
Bayer AG Planning Joint Venture to Make Drugs in Russia PDF Print E-mail
Friday, 14 October 2011 00:39

Germany's Bayer AG has joined a number of its peers in the pharmaceutical industry with the signing of an agreement that could see it set up additional manufacturing capacity in Russia.

Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 4 of 127